Kiromic Biopharma, Inc. Quarterly Debt-to-equity in % from Q2 2021 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Kiromic Biopharma, Inc. quarterly Debt-to-equity history and growth rate from Q2 2021 to Q2 2024.
  • Kiromic Biopharma, Inc. Debt-to-equity for the quarter ending June 30, 2024 was -298 %, a 17.1% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 -298 +61.5 +17.1% Jun 30, 2024
Q1 2024 -294 +2.92K +90.8% Mar 31, 2024
Q4 2023 -290 -457 -273% Dec 31, 2023
Q3 2023 -314 -364 -728% Sep 30, 2023
Q2 2023 -360 -379 -1984% Jun 30, 2023
Q1 2023 -3.21K -3.23K -23594% Mar 31, 2023
Q4 2022 167 +157 +1511% Dec 31, 2022
Q3 2022 50.1 +40.1 +404% Sep 30, 2022
Q2 2022 19.1 -8.18 -30% Jun 30, 2022
Q1 2022 13.7 Mar 31, 2022
Q4 2021 10.4 Dec 31, 2021
Q3 2021 9.93 Sep 30, 2021
Q2 2021 27.3 Jun 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.